Toxicity Of AstraZeneca's Vandetanib Expected Focus For FDA Advisory Committee

FDA will ask its Oncologic Drugs Advisory Committee at a Dec. 2 meeting whether the thyroid cancer drug should be limited to only those patients with progressive, symptomatic disease and if post-marketing studies are needed to determine the optimal dose.